常染色体显性肾小管间质肾病-尿调节素被误诊为局灶节段性肾小球硬化或遗传性肾小球疾病
研究回顾了8个携带UMOD变异的家系,其中21%(7/34)患者活检证实为FSGS。这些患者多表现为常染色体显性遗传、亚肾病范围蛋白尿、轻微血尿和肾功能损害,肾活检显示继发性FSGS特征。结论是常规临床和病理检查无法诊断ADTKD-UMOD,基因检测可确立诊断,对FSGS组织学患者应扩大基因检测范围。
要点
- UMOD变异患者可表现为FSGS组织学,易被误诊为原发性FSGS。
- ADTKD-UMOD临床特征包括显性遗传、亚肾病蛋白尿、轻微血尿和肾功能损害。
- 对FSGS组织学患者进行基因检测不应仅限于足细胞功能基因。
核心结论
- 常规临床和肾活检无法诊断ADTKD-UMOD,患者常被标记为FSGS。
- 基因检测可确立ADTKD-UMOD继发FSGS的诊断。
研究设计与样本
- 回顾性研究纳入8个携带UMOD变异的家系,收集临床、实验室和病理数据。
- 通过Sanger测序进行UMOD基因确认。
主要发现
- 活检证实的FSGS见于21%(7/34)的UMOD变异患者。
- 7个家系的UMOD变异为先前报道的ADTKD-UMOD突变。
- 一个三代受累家系中发现非经典转录本变异p.R79G与疾病共分离。
- 多数患者表现为常染色体显性遗传、亚肾病范围蛋白尿、轻微血尿和肾功能损害。
- 肾活检显示继发性FSGS特征,包括局灶硬化和部分足细胞足突融合。
临床怎么用
- 对FSGS组织学患者应考虑UMOD基因检测,尤其有显性遗传家族史时。
- 基因检测 panel 应包含UMOD等肾小管间质肾病基因,不限于足细胞基因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Focal segmental glomerulosclerosis (FSGS) is a histopathologically defined kidney lesion. FSGS can be observed with various underlying causes, including highly penetrant monogenic renal disease. We recently identified pathogenic variants of UMOD, a gene encoding the tubular protein uromodulin, in 8 families with suspected glomerular disease. METHODS: To validate pathogenic variants of UMOD, we reviewed the clinical and pathology reports of members of 8 families identified to have variants of UMOD. Clinical, laboratory, and pathologic data were collected, and genetic confirmation for UMOD was performed by Sanger sequencing. RESULTS: Biopsy-proven cases of FSGS were verified in 21% (7 of 34) of patients with UMOD variants. The UMOD variants seen in 7 families were mutations previously reported in autosomal dominant tubulointerstitial kidney disease-uromodulin (ADTKD-UMOD). For one family with 3 generations affected, we identified p.R79G in a noncanonical transcript variant of UMOD co-segregating with disease. Consistent with ADTKD, most patients in our study presented with autosomal dominant inheritance, subnephrotic range proteinuria, minimal hematuria, and renal impairment. Kidney biopsies showed histologic features of glomerular injury consistent with secondary FSGS, including focal sclerosis and partial podocyte foot process effacement. CONCLUSION: Our study demonstrates that with the use of standard clinical testing and kidney biopsy, clinicians were unable to make the diagnosis of ADTKD-UMOD; patients were often labeled with a clinical diagnosis of FSGS. We show that genetic testing can establish the diagnosis of ADTKD-UMOD with secondary FSGS. Genetic testing in individuals with FSGS histology should not be limited to genes that directly impair podocyte function.
引用
- Chun J, Wang M, Wilkins MS, et al. Autosomal Dominant Tubulointerstitial Kidney Disease-Uromodulin Misclassified as Focal Segmental Glomerulosclerosis or Hereditary Glomerular Disease. Kidney Int Rep. 2020. PMID: 32274456. doi:10.1016/j.ekir.2019.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。